Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
96.5M
-
Number of holders
-
166
-
Total 13F shares, excl. options
-
80.5M
-
Shares change
-
+3.56M
-
Total reported value, excl. options
-
$712M
-
Value change
-
+$33.2M
-
Put/Call ratio
-
4.59
-
Number of buys
-
92
-
Number of sells
-
-78
-
Price
-
$8.85
Significant Holders of AVADEL PHARMACEUTICALS PLC - Common Stock (AVDL) as of Q2 2025
210 filings reported holding AVDL - AVADEL PHARMACEUTICALS PLC - Common Stock as of Q2 2025.
AVADEL PHARMACEUTICALS PLC - Common Stock (AVDL) has 166 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 80.5M shares
of 96.5M outstanding shares and own 83.43% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (11.1M shares), BlackRock, Inc. (6.8M shares), BRANDES INVESTMENT PARTNERS, LP (6.49M shares), Two Seas Capital LP (6.16M shares), VANGUARD GROUP INC (5.56M shares), GENDELL JEFFREY L (5.18M shares), Polar Capital Holdings Plc (4M shares), Vivo Capital, LLC (2.68M shares), WEALTH EFFECTS LLC (2.35M shares), and GEODE CAPITAL MANAGEMENT, LLC (2.17M shares).
This table shows the top 166 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.